The Houston Open has battled rain over the first few days, but the weekend should be a little drier. Darkness disallowed the completion of the second round, which will pick back up at 8:30 a.m ...

Deborah Fuller receives funding from the National Institutes Health. The personal views expressed here are those of the authors. Patrick Mitchell receives funding from the National Institutes of ...

We've been tracking the cut line at the 2025 Houston Open to see which prominent golfers will and won't make it to the weekend at Memorial Park Golf Course. The second round stretched from ...

Apple’s latest array of Final Cut updates includes a wide variety of features. Apple Intelligence makes its first appearance with the new Image Playground support. But there are also a bunch of ...

Add articles to your saved list and come back to them any time. Public servants in the federal health, education and veterans’ departments have been singled out as the Coalition ups its promise ...

TACTI-004 will evaluate Immutep’s eftilagimod alfa, a first-in-class MHC Class II agonist, in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) ...

The 69-year-old momager showed off a chic bob on Instagram on March 24, opting for longer locks than her usual signature pixie cut. She slicked her dark hair back and down, where it sat neatly ...

TACTI-004 will evaluate Immutep’s eftilagimod alfa, a first-in-class MHC Class II agonist, in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA ...

TACTI-004 trial evaluates efti with Keytruda and chemotherapy for advanced NSCLC, focusing on progression-free and overall survival. Efti's unique MHC Class 2 agonist mechanism shows strong efficacy ...

The tariff cut decision was not final, with other options under discussion such as sectoral adjustments of tariffs and product-by-product negotiations rather than a wide cut, said one of the ...

"Even with the cuts DOGE is making, we're still running at a deficit," he told GoBankingRates.com, adding that it didn't make financial sense to cut and then continue to give money away.

Immutep (ASX:IMM) has announced that the first patient has been dosed in its pivotal TACTI-004 Phase 3 clinical trial. The trial is evaluating eftilagimod alfa, an innovative MHC Class 2 agonist, in ...